Target Price | $22.09 |
Price | $3.25 |
Potential |
579.72%
register free of charge
|
Number of Estimates | 11 |
11 Analysts have issued a price target Iovance Biotherapeutics Inc 2026 .
The average Iovance Biotherapeutics Inc target price is $22.09.
This is
579.72%
register free of charge
$32.00
884.62%
register free of charge
$10.00
207.69%
register free of charge
|
|
A rating was issued by 13 analysts: 12 Analysts recommend Iovance Biotherapeutics Inc to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Iovance Biotherapeutics Inc stock has an average upside potential 2026 of
579.72%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 164.07 | 452.85 |
13,687.39% | 176.01% | |
EBITDA Margin | -214.34% | -51.54% |
99.40% | 75.95% | |
Net Margin | -238.14% | -53.17% |
99.51% | 77.67% |
10 Analysts have issued a sales forecast Iovance Biotherapeutics Inc 2025 . The average Iovance Biotherapeutics Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Iovance Biotherapeutics Inc EBITDA forecast 2025. The average Iovance Biotherapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Iovance Biotherapeutics Inc Analysts have issued a net profit forecast 2025. The average Iovance Biotherapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.28 | -0.79 |
32.28% | 38.28% | |
P/E | negative | |
EV/Sales | 1.77 |
11 Analysts have issued a Iovance Biotherapeutics Inc forecast for earnings per share. The average Iovance Biotherapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Iovance Biotherapeutics Inc...
Analyst | Rating | Action | Date |
---|---|---|---|
Chardan Capital |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
Goldman Sachs |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
Truist Securities |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
Baird |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
Piper Sandler |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
Piper Sandler |
Locked
➜
Locked
|
Locked | Jan 31 2025 |
Analyst Rating | Date |
---|---|
Locked
Chardan Capital:
Locked
➜
Locked
|
Mar 03 2025 |
Locked
Goldman Sachs:
Locked
➜
Locked
|
Mar 03 2025 |
Locked
Truist Securities:
Locked
➜
Locked
|
Mar 03 2025 |
Locked
Baird:
Locked
➜
Locked
|
Feb 28 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 28 2025 |
Locked
Piper Sandler:
Locked
➜
Locked
|
Feb 28 2025 |
Locked
Piper Sandler:
Locked
➜
Locked
|
Jan 31 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.